ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
INDUSTRY AVERAGE RATING & OVERVIEW
Average ValuEngine Rating
The ValuEngine Rating is an overall
assessment of a stock's attractiveness.
It combines the following five factors:
valuation, risk-return tradeoff,
momentum, market capitalization, and
forecasted future returns. Only two
percent of the stock universe receives
the highest 5-engine rating, while the
lowest rating is a single engine. The
chart on the left shows historically how
stocks in the various ratings have
performed on average. Average
ValuEngine Rating for a sector is the
average of the ValuEngine Ratings for
all stocks in the sector.
TABLE OF CONTENTS
• Industry Average Rating & Overview
1
• Industry/Sector Comparison
2
• Best Performance Stocks
3
• Top and Bottom Stocks
4
• Annual Financials
6
• Quarterly Financials
8
• VE's Methodology & Disclaimer
3 out of 5
10
For a complete listing of ValuEngine ratings, fair
market valuations, one year target prices for all
stocks covered, please see the ValuEngine
Comprehensive Rating Report.
INDUSTRY OVERVIEW
# of Companies
Latest
Market Cap (bil.)
Earnings (mil.)
Revenue (bil.)
138
916.36
35,908.96
216.00
Percentage of Sector
9.80%
11.76%
11.18%
6.67%
Percentage of Market
1.69%
1.26%
0.89%
0.58%
AVERAGE FORECAST RETURN
One Month
Three Months
Six Months
One Year
Two Years
Three Years
0.17%
-0.10%
-0.70%
2.22%
0.32%
-3.53%
Average Forecast
RECENT STOCK PERFORMANCE
Average Realized Return
One Month
Three Months
Six Months
Last Year
7.69%
2.06%
-15.22%
-25.00%
VALUATION & RANKINGS
Avg Valuation
Avg Sharpe Ratio
6.64% undervalued
-0.4074
Avg Valuation Rank
63
Avg Sharpe Ratio Rank
40
Avg Size Rank
44
Avg Market Cap (bil.)
6.74
Avg 12 Month Return
-25.00%
Avg Momentum Rank
38
Avg 5 Yr Annual Return
-13.33%
Avg 5 Yr Annual Rtn Rank
39
Avg Expected EPS Growth
39.57%
Avg EPS Growth Rank
57
Avg P/E Ratio
26.8061
Avg P/E Rank
34
6.2550
Avg Market/Book Rank
48
3.6966
Avg Price/Sales Rank
50
Avg Volatility Rank
31
Avg Market/Book
Avg Price/Sales
Avg Volatility
71.86%
Just as important as the percentages shown for our ten predictive variables for each stock is the way they are ranked against the
8000 plus stocks in our database. This is sometimes confusing to newcomers to ValuEngine.com. Each of these quantitative
measurements is ranked on a scale of 1 to 100. Generally the higher the ranking, the more positive the influence each
measurement has on the overall attractiveness of the stock. In other words a high rank is always better. For example:
• Valuation rank 70: 30% of stocks are more undervalued
• Momentum rank 70: 30% of stocks have higher momentum
• Sharpe Ratio rank 70: 30% of stocks have a higher Sharpe Ratio
• Volatility rank 70: 30% of stocks have less volatility
• Size rank 70: 30% of companies have higher market capitalization
• P/E rank 70: 30% of stocks have lower P/E ratios
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 1
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
INDUSTRY / SECTOR / MARKET COMPARISON
INDUSTRY / SECTOR INFORMATION
Industry Code
Name
Industry
104
Medical Products
Industry Comparable
103
Medical Instruments
Industry Comparable
285
Medical Services
Industry Comparable
111
Medical-Outpnt/Hm Care
Industry Comparable
110
Medical-Nursing Homes
Sector
Medical
VALUATION & MOMENTUM COMPARISON
Industry Code
Avg Valuation
Avg Valuation Rank
Avg Sharpe Ratio
Avg Sharpe Ratio Rank
104
103
285
111
110
Sector
-6.64%
5.81%
16.51%
1.17%
-14.89%
2.62%
63
53
48
49
68
60
-0.4074
-0.3077
-0.4563
-0.3391
0.2109
-0.4589
0.1583
74
40
43
37
46
60
35
6.7379
5.7550
3.6916
3.2630
2.7778
5.5588
Avg Size Rank
44
43
45
51
66
40
Avg Momentum
-25.00%
-18.64%
-32.73%
-17.97%
-17.73%
-19.56%
Avg Market Cap (bil.)
Avg Momentum Rank
S&P 500
-9.18%
38
40
33
41
50
39
53
Avg Ann Return
-13.33%
-12.53%
-23.35%
-10.54%
2.05%
-24.52%
3.05%
Avg Return Rank
39
44
36
48
60
33
70
Avg EPS Growth
39.57%
42.86%
53.00%
36.43%
6.23%
25.34%
Avg Growth Rank
Avg P/E Ratio
Avg E/P Ratio Rank
Avg M/B Ratio
Avg M/B Ratio Rank
Avg P/S Ratio
Avg P/S Ratio Rank
Avg Volatility
Avg Volatility Rank
Avg Alpha
Avg Alpha Rank
Avg Beta
Avg Beta Rank
57
56
54
45
38
49
26.8061
34.2274
26.1699
28.5904
22.9038
27.3146
34
29
34
40
33
25
6.2550
7.0576
5.7088
4.1113
2.7148
5.0766
48
39
46
48
50
50
3.6966
11.2360
4.5862
1.3029
0.9260
10.9175
50
34
55
65
76
34
71.86%
72.02%
79.45%
59.05%
44.89%
81.67%
19.24%
31
30
27
36
44
25
77
-0.1808
-0.0292
-0.1110
-0.0478
-0.0714
-0.1017
0.0000
38
47
43
45
50
43
56
1.1691
1.0697
1.0477
0.9678
1.2380
1.0247
1.0000
40
41
42
47
30
44
41
FORECAST COMPARISON
104
103
285
111
110
Sector
Avg One Month Forecast
Industry Code
0.17%
0.24%
-0.04%
-0.35%
0.33%
0.17%
Avg Three Month Forecast
-0.10%
0.24%
-0.11%
-0.33%
0.50%
-0.22%
Avg Six Month Forecast
-0.70%
0.33%
0.56%
0.54%
-0.76%
-0.90%
Avg One Year Forecast
2.22%
3.05%
-0.04%
-4.08%
3.97%
2.17%
Avg Two Year Forecast
0.32%
7.24%
6.64%
1.27%
7.06%
3.33%
Avg Three Year Forecast
-3.53%
6.24%
0.69%
-2.63%
15.21%
-0.59%
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 2
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
BEST PERFORMANCE STOCKS
One Month Return
Forecast Return
Rating
PLSH
Ticker
PANACEA LIFESCI
Company Name
Realized Return
177.75%
-41.09%
1
Market Cap
0.00
LUCY
INNOVATIVE EYEW
121.70%
-33.18%
1
0.02
UTRS
MINERVA SURGICL
114.91%
-30.25%
1
0.01
BGXX
BRIGHT GREEN CP
108.33%
-30.12%
1
0.17
CTSO
CYTOSORBENTS CP
76.77%
-18.01%
1
0.15
HUGE
FSD PHARMA INC
75.00%
-20.33%
1
0.06
OMER
OMEROS CORP
72.95%
-18.53%
1
0.32
MHUA
MEIHUA INTL MED
71.32%
-20.30%
1
0.38
Realized Return
Forecast Return
Rating
Three Month Return
Ticker
Company Name
Market Cap
RMTI
ROCKWELL MED
135.51%
-16.14%
1
0.02
CTSO
CYTOSORBENTS CP
134.90%
-18.01%
1
0.15
TGTX
TG THERAPEUTICS
112.34%
-8.50%
2
2.60
PLSH
PANACEA LIFESCI
106.70%
-41.09%
1
0.00
APYX
APYX MEDICAL CP
91.95%
-9.77%
2
0.12
BGXX
BRIGHT GREEN CP
91.86%
-30.12%
1
0.17
OMER
OMEROS CORP
90.21%
-18.53%
1
0.32
LUCY
INNOVATIVE EYEW
85.04%
-33.18%
1
0.02
Realized Return
Six Month Return
Forecast Return
Rating
MHUA
Ticker
MEIHUA INTL MED
Company Name
354.74%
-20.30%
1
Market Cap
0.38
PLSH
PANACEA LIFESCI
146.89%
-41.09%
1
0.00
TGTX
TG THERAPEUTICS
124.87%
-8.50%
2
2.60
CTSO
CYTOSORBENTS CP
79.49%
-18.01%
1
0.15
HUGE
FSD PHARMA INC
65.59%
-20.33%
1
0.06
SHWGF
SHANDONG WEIGAO
57.55%
5.18%
4
7.55
QTRX
QUANTERIX CORP
53.97%
7.74%
4
0.49
SMTI
SANARA MEDTECH
50.53%
10.00%
4
0.35
Realized Return
Forecast Return
Rating
-4.69%
3
4.01
One Year Return
Ticker
Company Name
Market Cap
LNTH
LANTHEUS HLDGS
109.98%
VMD
VIEMED HEALTHCR
86.70%
5.60%
4
0.32
HUGE
FSD PHARMA INC
75.94%
-20.33%
1
0.06
TGTX
TG THERAPEUTICS
72.28%
-8.50%
2
2.60
SMTI
SANARA MEDTECH
68.50%
10.00%
4
0.35
ZYXI
ZYNEX INC
67.42%
22.65%
5
0.47
HAE
HAEMONETICS CP
38.93%
3.87%
3
4.08
SHWGF
SHANDONG WEIGAO
28.46%
5.18%
4
7.55
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 3
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
TOP AND BOTTOM STOCKS
Valuation - Top undervalued Stocks
Ticker
Valuation - Top Overvalued Stocks
Company Name
Valuation
Ranking
Ticker
Company Name
Valuation
Ranking
CLRB
CELLECTAR BIOSC
-75.00%
100
HSTO
HISTOGEN INC
300.00%
1
NEPT
NEPTUNE WELLNES
-75.00%
98
MYO
MYOMO INC
300.00%
1
PHGE
BIOMX INC
-75.00%
98
ZYXI
ZYNEX INC
64.90%
7
VAPO
VAPOTHERM INC
-75.00%
97
VMD
VIEMED HEALTHCR
52.26%
9
ACB
AURORA CANNABIS
-75.00%
100
LMAT
LEMAITRE VASCLR
36.20%
14
HEXO
HEXO CORP
-75.00%
99
PHG
KONINKLIJKE PHL
33.65%
15
CGC
CANOPY GROWTH
-75.00%
99
PODD
INSULET CORP
31.14%
17
SURF
SURFACE ONCOLGY
-74.45%
96
SYK
STRYKER CORP
27.07%
20
One Year Forecast Return - Top Stocks
Ticker
Company Name
One Year Forecast Return - Bottom Stocks
Forecast Return
Ranking
Ticker
Company Name
Forecast Return
Ranking
VAPO
VAPOTHERM INC
50.85%
100
PLSH
PANACEA LIFESCI
-41.09%
1
SNES
SENESTECH INC
34.36%
100
LUCY
INNOVATIVE EYEW
-33.18%
1
SMFL
SMART FOR LIFE
29.27%
100
UTRS
MINERVA SURGICL
-30.25%
1
JUPW
JUPITER WELLNES
27.72%
100
BGXX
BRIGHT GREEN CP
-30.12%
1
ZYXI
ZYNEX INC
22.65%
99
HUGE
FSD PHARMA INC
-20.33%
2
INLB
ITEM 9 LABS CP
21.15%
98
MHUA
MEIHUA INTL MED
-20.30%
2
IMCC
IM CANNABIS CP
19.73%
98
OMER
OMEROS CORP
-18.53%
2
LFLY
LEAFLY HOLDINGS
18.77%
97
CTSO
CYTOSORBENTS CP
-18.01%
2
Market Capital - Big Cap Stocks
Ticker
Company Name
Market Capital - Small Cap Stocks
ABT
ABBOTT LABS
Market Cap
(millions)
188,584.53
Ranking
100
HCYT
H-CYTE INC
MDT
MEDTRONIC
111,322.77
99
SNES
SENESTECH INC
1.40
2
SYK
STRYKER CORP
100,034.18
99
ASNB
EKIMAS CORP
3.12
3
ESLOY
ESSILORLUXOTTIC
80,825.56
99
PLSH
PANACEA LIFESCI
3.28
3
BSX
BOSTON SCIENTIF
67,648.00
98
KERN
AKERNA CORP
3.30
3
LZAGY
LONZA GROUP AG
44,011.18
96
BRSH
BRUUSH ORAL CAR
3.65
3
HLN
HALEON PLC ADS
37,030.67
95
MYO
MYOMO INC
3.67
3
RMD
RESMED INC
31,310.93
95
CMPD
COMPUMED INC
3.81
4
Momentum
Ranking
Momentum - Top Stocks
Ticker
Company Name
Ticker
Company Name
Market Cap
(millions)
1.06
Ranking
1
Momentum - Bottom Stocks
Ticker
Company Name
Momentum
Ranking
LNTH
LANTHEUS HLDGS
109.98%
99
IMCC
IM CANNABIS CP
-95.45%
1
VMD
VIEMED HEALTHCR
86.70%
99
HCYT
H-CYTE INC
-93.86%
1
HUGE
FSD PHARMA INC
75.94%
98
AYRWF
AYR WELLNESS
-91.26%
1
TGTX
TG THERAPEUTICS
72.28%
98
SNES
SENESTECH INC
-88.15%
1
SMTI
SANARA MEDTECH
68.50%
98
HEXO
HEXO CORP
-85.00%
2
ZYXI
ZYNEX INC
67.42%
98
HSTO
HISTOGEN INC
-79.75%
3
HAE
HAEMONETICS CP
38.93%
95
NEPH
NEPHROS INC
-76.86%
3
SHWGF
SHANDONG WEIGAO
28.46%
93
NVIV
INVIVO THERAPT
-75.72%
4
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 4
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
TOP AND BOTTOM STOCKS
Expected EPS Growth - Top Stocks
Ticker
Company Name
Expected EPS Growth - Bottom Stocks
EPS Growth
Ranking
Ticker
Company Name
EPS Growth
Ranking
INFU
INFUSYSTEM HLDG
670.45%
98
LHDX
LUCIRA HEALTH
-206.47%
1
MRMD
MARIMED INC
566.67%
98
CMRX
CHIMERIX INC
-143.20%
2
FTLF
FITLIFE BRANDS
345.45%
97
OSUR
ORASURE TECH
-128.88%
2
VMD
VIEMED HEALTHCR
154.92%
92
HUGE
FSD PHARMA INC
-99.83%
2
SMFL
SMART FOR LIFE
153.86%
92
MRVI
MARAVAI LFS HLD
-75.61%
3
BLFS
BIOLIFE SOL INC
145.80%
92
NEOG
NEOGEN CORP
-66.87%
4
AHCO
ADAPTHEALTH CP
123.70%
90
MGNX
MACROGENICS INC
-64.70%
4
CRLBF
CRESCO LABS INC
119.39%
90
QDEL
QUIDELORTHO CP
-62.91%
4
E/P Ratio - Top Stocks
Ticker
Company Name
E/P Ratio - Bottom Stocks
E/P Ratio
Ranking
Ticker
Company Name
E/P Ratio
Ranking
CMRX
CHIMERIX INC
1.1473
100
NEPT
NEPTUNE WELLNES
-8.8556
1
ZIMV
ZIMVIE INC
0.1657
93
SNES
SENESTECH INC
-7.2489
1
QDEL
QUIDELORTHO CP
0.1556
92
NVIV
INVIVO THERAPT
-5.4739
1
MRVI
MARAVAI LFS HLD
0.1170
86
SMFL
SMART FOR LIFE
-4.0271
2
OMI
OWENS & MINOR
0.1136
85
IMCC
IM CANNABIS CP
-3.9575
2
BTMD
BIOTE CORP
0.1039
83
HSTO
HISTOGEN INC
-3.5466
2
BAX
BAXTER INTL
0.0818
75
VAPO
VAPOTHERM INC
-3.2448
2
PAHC
PHIBRO ANIMAL
0.0787
74
MYO
MYOMO INC
-3.0122
2
Sharpe Ratio - Top Stocks
Ticker
Company Name
Sharpe Ratio - Bottom Stocks
Sharpe Ratio
Ranking
Ticker
Company Name
Sharpe Ratio
Ranking
BABYF
ELSE NUTRN HLDG
5.1994
100
BGXX
BRIGHT GREEN CP
-3.3265
1
GSD
GLOBAL SYS DYN
2.7956
100
BRSH
BRUUSH ORAL CAR
-2.8728
1
FTLF
FITLIFE BRANDS
1.1852
97
SMFL
SMART FOR LIFE
-2.3282
1
STSS
SHARPS TECH INC
0.9000
96
IMCC
IM CANNABIS CP
-1.9230
2
PODD
INSULET CORP
0.7569
96
VRNOF
VERANO HLDGS CP
-1.8918
2
HLN
HALEON PLC ADS
0.7486
95
UTRS
MINERVA SURGICL
-1.8884
2
RMD
RESMED INC
0.6153
94
AYRWF
AYR WELLNESS
-1.8350
2
ABT
ABBOTT LABS
0.5919
94
HITI
HIGH TIDE INC
-1.6493
2
Volatility - Less Volatile Stocks
Ticker
Company Name
Volatility - Top Volatile Stocks
Volatility
Ranking
Ticker
Company Name
Volatility
Ranking
GSD
GLOBAL SYS DYN
1.55%
92
AKAN
AKANDA CP
259.60%
1
KVSA
KHOSLA VNTR ACQ
5.12%
88
LHDX
LUCIRA HEALTH
180.88%
3
ABT
ABBOTT LABS
19.45%
77
PLSH
PANACEA LIFESCI
167.39%
4
MDT
MEDTRONIC
21.18%
74
HCYT
H-CYTE INC
151.32%
5
BSX
BOSTON SCIENTIF
22.78%
71
GHSI
GUARDION HEALTH
149.30%
5
BAX
BAXTER INTL
23.89%
68
SNDL
SNDL INC
144.47%
5
SYK
STRYKER CORP
24.50%
67
UTRS
MINERVA SURGICL
135.58%
6
SNN
SMITH & NEPHEW
24.98%
67
LUCY
INNOVATIVE EYEW
130.26%
7
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 5
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
ANNUAL FINANCIALS (ALL ITEMS IN MILLIONS)
2022 (21)
2021 (132)
2020 (128)
2019 (115)
2018 (106)
2017 (89)
Cash
BALANCE SHEET (# of company)
7,708.97
52,161.93
52,299.96
34,100.83
26,156.67
30,725.88
Marketable Securities
7,816.27
15,401
11,614.49
10,852.55
11,701.83
11,077.58
Receivables
8,453.89
41,177.91
38,989.67
40,197.91
36,347.36
31,536.01
8,789
40,675.86
37,963.38
35,036.28
30,175.21
26,262.82
1,820.72
9,059.1
7,876.53
5,308.74
4,792.57
4,162.14
805.74
4,626.93
3,780.46
2,681.41
2,491.81
2,061.28
4,164.22
21,716.38
20,102.62
16,247.71
14,551.67
12,655.46
74.49
34.76
217.87
135.75
2.7
Inventory
Raw Materials
Work in Progress
Finished Goods
Notes Receivable
--
Other Current Assets
3,152.24
14,383.17
13,690.31
10,926.63
12,781.17
12,299.25
Total Current Assets
35,921.38
163,875.41
154,591.48
131,334.39
117,298.04
111,904.88
Property, Plant & Equipment
18,825.11
104,873.66
103,130.52
89,097.51
73,640.14
78,334.96
Accumulated Depreciation
10,730.39
56,831.13
55,072.16
47,697.2
39,929.21
43,220.78
Net Property, Plant & Equipment
11,088.39
53,116.5
52,343.19
49,215.38
39,508.27
36,607.23
158.79
18,477.84
11,928.29
7,162.35
5,380.38
3,272.6
Investment & Advances
Other non-current Assets
5.39
580.5
457.19
453.22
519.76
627.42
3,699.44
19,681.23
16,570.35
13,890.11
8,403.7
6,112.76
66,832.67
279,284.41
249,542.33
254,187.45
238,974.28
207,604.48
4,461.73
25,140.59
12,238.19
9,153.39
18,032.35
13,451.06
122,369.89
567,390.75
502,827.28
470,293.72
428,117.12
379,581.09
243.75
1,289.12
2,124.41
2,370.19
2,299.73
1,226.51
Accounts Payable
3,801.75
23,515.79
23,744.23
21,969.86
19,926.78
15,091.17
Current Portion of Long-term Debt
4,016.44
8,377.75
9,682.49
8,558.77
9,842.92
14,699.96
Deferred Charges
Intangibles
Deposits & other assets
TOTAL ASSETS
Notes Payable
Current Portion of Capital Leases
9.09
72.14
63.26
51.68
11.33
7.57
6,396.08
26,327.8
22,073.86
19,634.12
19,387.11
18,743.61
882.87
3,200.15
2,669.91
2,228.63
2,483.12
2,033.06
Other Current Liabilities
1,146.77
19,170.44
15,557.28
13,590.35
14,966.46
10,854.46
Total Current Liabilities
16,528.51
83,243.22
76,846.49
69,258.35
68,918.52
62,658.69
Accrued Expenses
Income Taxes Payable
Mortgages
Deferred Charges (taxes/income)
--
--
--
--
--
2.45
1,201.24
11,313.55
9,925.97
9,904.49
8,900.71
8,547.84
Convertible Debt
157.74
1,171.41
1,172.26
1,734.78
829.97
1,577.71
Long Term Debt
26,691.12
132,380.45
118,002.06
106,059.62
94,214.86
98,657.59
38.66
420.35
363.03
254.55
20.02
18.99
Other Long-Term Liabilities
5,550.45
37,197.24
33,539.08
30,326.47
27,821.32
27,861.02
Minority Interest (liabilities)
28.88
3,113.97
2,858.62
62.13
269.63
14.27
50,375.05
273,354.47
246,834.58
221,588.17
200,976.91
199,339.23
11.12
276.16
19.38
108.68
3.01
Non-Current Capital Leases
Total Liabilities
Preferred Stock
--
Common Stock, Net
14,298.34
55,231.69
48,919.29
46,821.66
36,423.34
33,962.43
Capital Surplus
31,727.58
137,298.73
130,600.47
119,267.71
110,908.6
87,809.63
Retained Earnings
29,464.51
126,771.94
127,720.06
114,337.7
100,606.97
94,931.39
1,725.36
37,707.21
34,322.41
33,305.04
32,645.46
30,768.18
Other Equity
-1,769.26
300.53
-17,202.31
1,565.26
5,306.19
-5,697.61
Total Shareholders' Equity
71,995.84
292,651.97
255,992.86
248,706.67
227,141.39
180,241.7
122,369.89
567,390.75
502,827.28
470,293.72
428,117.12
379,581.09
Treasury Stock
Total Liabilites & Shareholders Equity
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 6
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
ANNUAL FINANCIALS (ALL ITEMS IN MILLIONS)
2022 (23)
2021 (132)
2020 (128)
2019 (117)
2018 (106)
2017 (91)
Net Sales or Revenues
INCOME STATEMENT (# of company)
97,930.59
248,737.05
215,504.44
216,186.25
199,755.97
179,432.33
Cost of Goods Sold
38,041.74
114,326.16
99,683.74
95,776.95
87,996.43
78,323.07
Gross Profit
53,367.04
134,410.89
115,820.7
120,408.61
111,759.41
97,786.58
Research & Development Expense
6,211.93
16,166.71
14,559.65
14,658.04
13,338.96
12,236.79
Selling, General & Admin. Expense
28,083.75
82,242.09
73,762.87
73,564.7
67,256.54
59,566.63
Income Before Depr., Depl., Amort.
19,071.35
36,002.12
27,498.18
32,185.85
31,163.91
25,983
Depreciation, Depletion, Amort.
3,935.98
6,648.7
7,138.39
6,043.9
7,847.35
5,996.92
Non-Operating Income
-519.19
4,936.96
2,338.63
1,218.55
1,330.18
1,101.47
Interest Expense
1,187.5
3,852.48
4,154.06
4,469.01
3,765.27
3,297.64
13,427.68
30,477.39
18,566.63
22,928.31
20,922.96
17,807.95
2,306.76
5,913.35
2,468.03
-498.29
3,557.27
4,586.48
36.62
694.04
288.08
281.44
190.14
291
-2.38
-2.68
-2.01
-0.55
1.95
Pretax Income
Provision for Income Taxes
Minority Interest
Investment Gains (Losses)
--
Other Income
--
Income Before Extraordinaries & Disc Oper.
--
--
--
--
24,565.28
16,094.77
23,420.28
17,365.14
13,654.38
8,186.71
79.22
-200.71
-228.84
1,077.48
12,358.63
31,849.29
15,884.9
22,939.25
16,946.16
14,439.74
6,318.25
21,083.8
20,069.07
19,192.34
17,998.83
17,229.15
Average Shares used for Basic EPS
6,302.75
20,709.23
19,956.62
19,056.41
17,833.11
17,064.25
Income Before Non-Recurring Items
19,505.56
28,493.42
28,651.67
29,907.81
28,801.67
24,075.57
Income From Non-Recurring Items
-7,123.16
-8,306.17
-12,408.27
-6,495.94
-11,195.5
-11,034.46
EPS - Basic, net
-37.01
17.24
-253.01
-1,621.11
-4,216.78
-16,663.93
EPS - Diluted, net
-39.02
45.54
-255.07
-1,540.03
-4,214.07
-16,088.93
-0.84
-30.15
-215.94
-1,552.16
-2,337.64
-14,687.24
Extraordinary Items & Discontinued Oper.
Net Income
Average Shares used for Diluted EPS
EPS - Diluted, before non-recurring Items
CASH FLOW STATEMENT (# of company)
12,394.26
--
--
2022 (21)
2021 (132)
2020 (128)
2019 (115)
2018 (106)
2017 (89)
Net Income (Cash Flow)
4,386.95
28,983.67
12,604.72
22,142.27
17,317.44
14,743.31
Depreciation, Depletion, Amortization-CF
3,933.77
20,114.27
20,076.89
17,692.48
16,449.38
15,158.72
-1,794.43
-4,252.67
-1,330.59
-7,134.25
-4,202.66
107.23
-5,265.14
15.22
165.33
257.2
-961.93
Net Increase(decrease) in Assets/Liabilities
Cash from(used in) Discontinued Oper.
--
Other Adjustments - Net
1,982.62
2,774.52
7,439.65
352.47
-709.21
-1,243.51
Net Cash from (used by) Operating Act.
8,508.92
42,356.37
38,806.3
33,214.06
29,112.38
27,804.78
Increase/Decrease in Prop, Plant, & Equ.
-2,251.96
-8,983.73
-12,054.99
-12,057.11
-9,615.74
-7,699.47
-466.91
-28,908.02
-7,643.64
-11,333.63
135.13
-19,030.43
-13.24
-4,348.78
-814.72
260.27
-867.1
314.17
43.03
8.13
-1,129.96
-850.14
-643.13
-320.57
Net Cash from (used by) Invesment Act.
-2,689.08
-42,346.36
-21,682.04
-23,978.48
-10,988.75
-26,737.59
Issuance (purchase) of Equity Shares
-1,892.87
521.84
5,277
779.18
-3,473.31
-4,515.07
-995.4
6,656.97
8,963.03
6,407.04
-12,585.66
-4,363.54
-21.4
-2,081.15
-2,661.61
3,756.78
-247.98
2,368.27
Payment of Dividends & Other Cash Dist.
-3,862.35
-10,380.14
-9,125.89
-9,220.27
-8,165.11
-7,382.66
Other Cash from (used by) Financing Act.
740.08
-479.68
-1,345.97
-3,414.37
-634.97
4,515.33
-6,031.96
-5,757.71
1,106.7
-1,692.79
-25,106.55
-9,376.63
-364.84
-1,420.32
17,963.24
7,467.06
-6,484.99
-7,110.95
Acquisition/Disposition of Subsidiaires
Increase (decrease) in Investments
Other Cash inflow from Investment Act.
Issuance (repayment) of Debt Securities
Increase (decrease) in Bank & Other
Net Cash from (used by) Financing Act.
Net Change in Cash & Cash Equivalents
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 7
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
QUARTERLY FINANCIALS (ALL ITEMS IN MILLIONS)
2022Q4 (5)
2022Q3 (120)
2022Q2 (128)
2022Q1 (121)
2021Q4 (132)
2021Q3 (121)
Cash
BALANCE SHEET (# of company)
5,293.82
25,964.51
31,405.5
31,928.61
50,518.46
36,346.56
Marketable Securities
6,797.01
11,008.05
11,790.79
12,952.57
15,672.54
12,419.94
Receivables
6,499.42
28,222.09
37,463.91
30,231.3
41,109.44
26,524.66
Inventory
6,287.98
31,909.44
40,182.92
31,902.63
40,904.36
28,352.78
Raw Materials
1,501.32
7,259.73
7,290.53
6,630.15
8,896.07
5,934.08
778.03
3,723.6
3,714.78
3,440.42
4,449.01
3,401.58
3,900.67
17,407.48
17,580.08
16,486.02
20,629.81
15,674.03
0.83
73.49
4.62
71.99
8.69
Work in Progress
Finished Goods
Notes Receivable
--
Other Current Assets
3,811.01
12,038.93
12,270.87
10,362.71
14,667.76
9,611.92
Total Current Assets
28,689.24
109,144.88
133,189.58
117,382.43
162,944.59
113,265.57
Property, Plant & Equipment
15,335.45
71,478.8
74,183.34
72,916.58
96,654.85
70,160.16
Accumulated Depreciation
9,108.64
39,578.59
40,573.81
40,159.11
52,010.08
38,962.31
Net Property, Plant & Equipment
6,374.97
37,967.14
46,545.14
41,143.65
53,210.91
36,015.62
36.35
9,811.28
11,685.59
12,393.27
18,497.72
18,820.48
Investment & Advances
Other non-current Assets
25.51
510.38
20.7
580.51
23.66
3,438.05
15,553.94
19,037.35
16,244.99
19,668.8
14,755.01
63,301.31
199,634.78
234,048.84
209,168.23
278,114.62
185,610.22
3,398.54
12,709.48
13,919.27
11,908.82
25,341.02
10,883.92
105,369.38
388,592.59
463,084.75
411,762.44
565,609.56
382,424.78
9.92
199.48
2,124.41
1,707.36
2,299.27
424.29
Accounts Payable
2,527.62
14,939.59
19,612.13
15,686.21
23,215.95
13,002.42
Current Portion of Long-term Debt
6,061.17
10,631.37
9,107.31
4,477.64
8,095.62
4,554.27
Deferred Charges
Intangibles
Deposits & other assets
TOTAL ASSETS
Notes Payable
Current Portion of Capital Leases
--
0.7
81.46
84.35
84.25
72.43
73.87
6,123.34
23,190.14
25,019.98
23,291.34
25,654.74
22,787.54
Income Taxes Payable
724.4
1,858.69
2,162.36
1,895.31
2,898.67
2,060.58
Other Current Liabilities
157.24
6,090.49
11,510.4
7,161.94
19,154.06
5,925.06
Total Current Liabilities
15,626.8
57,298.39
70,287.02
53,266.59
81,802.05
49,187.62
Accrued Expenses
Mortgages
Deferred Charges (taxes/income)
--
--
--
--
--
5,899.15
6,768.7
6,615.76
11,302.69
7,979.45
682.12
671.61
1,191.62
1,190.19
1,260.56
23,467.75
102,453.36
120,208.16
112,759.59
131,456.02
93,574.29
1.29
580.68
575.99
567.84
419.14
434.31
5,207.94
24,216.54
27,969.9
26,626.6
35,922
26,547.6
27.51
67.85
94.12
2,849.54
3,071.16
194,028.67
229,740.22
203,973.27
269,474.84
184,555.77
7.23
9.34
10.36
11.12
134.99
2,026.5
54,469.68
55,243.51
54,262.02
56,192.41
54,196.75
Capital Surplus
28,783.84
107,546.81
114,144.38
105,866.59
137,197.91
101,708.27
Retained Earnings
32,633.21
88,427.63
114,902.86
100,223.16
127,402.07
93,771.39
1,623.26
39,290.62
38,753.11
38,393.85
37,715.98
35,604.65
Other Equity
-2,338.23
-17,105.14
-12,653.24
-14,581.51
916.68
-16,722.78
Total Shareholders' Equity
59,482.07
194,563.88
233,345.53
207,790.16
294,749.41
197,869.02
105,369.38
388,592.59
463,084.75
411,762.44
565,609.56
382,424.78
Convertible Debt
Long Term Debt
Non-Current Capital Leases
Other Long-Term Liabilities
Minority Interest (liabilities)
Total Liabilities
Preferred Stock
Common Stock, Net
Treasury Stock
Total Liabilites & Shareholders Equity
1,469.1
--
--
-45,887.31
--
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 8
ValuEngine
ValuEngineInc
Industry Report for
TM
MEDICAL PRODUCTS
Report Date: Feb 13, 2023
QUARTERLY FINANCIALS (ALL ITEMS IN MILLIONS)
INCOME STATEMENT (# of company)
Net Sales or Revenues
Cost of Goods Sold
Gross Profit
2022Q4 (6)
2022Q3 (121)
2022Q1 (123)
2021Q4 (119)
2021Q3 (124)
18,997.84
50,138.43
2022Q2 (122)
53,192
52,806.11
54,151.29
50,895.71
7,753.87
24,229.73
24,708.98
23,919.16
24,274.36
22,164.24
11,244.94
25,753.8
28,411.12
27,456.72
28,006.66
27,167.34
Research & Development Expense
1,479.73
3,916.67
3,630.26
3,767.67
3,744.43
3,571.62
Selling, General & Admin. Expense
5,883.84
15,970.08
18,228.72
15,860.23
16,803.56
15,419.02
Income Before Depr., Depl., Amort.
3,881.37
5,867.04
6,552.13
7,828.82
7,458.68
8,176.7
929.31
5,817.53
1,648.14
1,610.07
1,683
1,675.46
82.36
-228.47
-1,816.9
-5,746.48
-2,264.49
5,578.81
Interest Expense
119.91
965.62
913.68
1,010.01
776.79
754.65
Pretax Income
2,915.5
-1,114.67
2,172.34
-559.04
2,754.34
11,324.68
1,301.74
Depreciation, Depletion, Amort.
Non-Operating Income
Provision for Income Taxes
525.82
631.95
-7.4
384.61
2,333.47
Minority Interest
8
62.63
22.04
79.84
41.66
156.65
Investment Gains (Losses)
--
-0.8
-0.96
-0.82
-0.9
-0.32
Other Income
--
--
-0.08
-0.72
0.03
Income Before Extraordinaries & Disc Oper.
Extraordinary Items & Discontinued Oper.
1,604.77
--
--
-1,631.7
1,360.44
-354.2
2,525.92
9,081.38
-57.63
20.92
32.31
387.49
2,995.06
Net Income
1,604.77
-1,689.34
1,379.95
-321.88
2,913.41
12,075.04
Average Shares used for Diluted EPS
3,805.92
15,026.7
14,935.12
14,605.49
13,969.88
14,022.37
Average Shares used for Basic EPS
3,802.62
14,878.49
14,648.89
14,330.06
13,875.94
13,717.17
Income Before Non-Recurring Items
3,766.29
6,493.22
7,069.97
7,837.82
7,798.9
7,978.77
-2,161.52
-8,121.26
-5,711.28
-8,185.39
-5,152.24
1,060.77
EPS - Basic, net
1.28
-58.58
-77.85
-183.42
-103.8
119.64
EPS - Diluted, net
1.28
-58.89
-91.6
-184.29
-104.24
115.87
EPS - Diluted, before non-recurring Items
3.15
-8.18
-14.99
-17.86
-4.79
-5.22
Income From Non-Recurring Items
2022Q4 (5)
2022Q3 (120)
2022Q2 (126)
2022Q1 (121)
2021Q4 (131)
2021Q3 (121)
Net Income (Cash Flow)
CASH FLOW STATEMENT (# of company)
1,726.83
3,407.51
8,284.71
6,602.95
28,356.75
12,248.01
Depreciation, Depletion, Amortization-CF
1,472.42
12,424.48
9,657
5,732.1
17,917.06
8,666.29
-1,484.71
-7,945.67
-8,767.38
-5,298.4
-5,368.57
-4,307.87
-1.14
-5.4
-0.5
-5,262.8
-2,047.12
411.83
5,514.55
5,318.17
2,475.16
1,539.59
2,548.81
2,126.37
13,398.73
14,488.09
9,505.51
37,183.73
17,107.15
Net Increase(decrease) in Assets/Liabilities
Cash from(used in) Discontinued Oper.
Other Adjustments - Net
Net Cash from (used by) Operating Act.
Increase/Decrease in Prop, Plant, & Equ.
--
-836.1
-4,728.99
-4,990.31
-3,119.14
-7,495.37
-4,855.8
-2,839.33
-15,096.91
-14,470.49
-9,401.85
-27,812.66
-2,575.53
Increase (decrease) in Investments
12.88
-218
-895.29
-1,614.22
-3,686.92
-1,984.39
Other Cash inflow from Investment Act.
40.99
278.86
-57.53
-146.08
602.46
1,156.14
-3,621.57
-19,764.04
-20,411.63
-14,280.3
-38,506.45
-8,259.57
-298.41
-2,971.44
-4,271.17
-2,633.49
-959.7
2,913.29
Issuance (repayment) of Debt Securities
2,083.99
2,077.03
7,558.03
4,164.66
5,656.17
-1,859.95
Increase (decrease) in Bank & Other
2,632.67
2,271.59
-2,284.54
104.07
-1,274.64
-337.89
Payment of Dividends & Other Cash Dist.
-1,935.93
-5,574.12
-7,489.86
-4,868.32
-8,631.34
-4,799.76
Other Cash from (used by) Financing Act.
390.99
30.92
589.16
474.77
-248.86
-958.86
Net Cash from (used by) Financing Act.
2,873.3
-4,166.03
-5,899.39
-2,757.29
-5,453.9
-5,043.15
Net Change in Cash & Cash Equivalents
1,146.6
-11,289.06
-12,480.94
-7,708.18
-2,731.03
3,609.8
Acquisition/Disposition of Subsidiaires
Net Cash from (used by) Invesment Act.
Issuance (purchase) of Equity Shares
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 9
Industry Report for
MEDICAL PRODUCTS
ValuEngine
ValuEngineInc
TM
Report Date: Feb 13, 2023
VALUENGINE'S METHODOLOGY & DISCLAIMER
ValuEngine's research combines the most advanced academic concepts with real world Wall Street practice. The result is state-ofthe-art fair market valuation and price forecasting technologies.
ValuEngine's stock valuation employs a sophisticated, three-factor approach. Fundamental variables, such as a company's trailing
12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's future 12-month EPS, and the 30-year
Treasury yield, are all used to create a more accurate reflection of a company's fair value. Together with eleven additional
variables, ValuEngine paints a detailed picture of a company's fair value, represented by the model price.
ValuEngine's stock forecasts capture several important tendencies that stock prices consistently exhibit over six time horizons to
ensure forecasts are established relative to a stock's proper peer groups. Advanced statistical/econometric techniques are used to
run thousands of simulations estimating the probability of a double in stock price, as well as the probability of meeting and
exceeding any given portfolio or stock investment target.
VE Engine Rating is an assessment of a stock's overall attractiveness. It is based on the one year forecast target price, which is the
final evolution of VE's equity modeling. On average, only 2 percent of ValuEngine's 5,500 stocks under coverage achieve a 5
rating. 5 and 4 rated stocks are expected to outperform the overall markets, 3 rated to roughly match market performance, and 2
and 1 rated are expected to underperform.
For additional information about ValuEngine's financial research and financial modeling, please click www.valuengine.com
DISCLOSURES
ValuEngine offers equity recommendations and related return estimates to investors and their advisors. It uses a three-class BuyHold-Sell rating system. This is a consolidated version of the firm's five class rating system: most favorable and favorable ratings
are buys; neutral ratings are holds and the categories unfavorable and most unfavorable are sells.
STOCK RATINGS: The terms below are used to rate a stock's 12-month performance:
1. Buy: Expected to outperform the SP500 producing above average returns.
2. Hold: Expected to perform in line with the SP500 with average returns.
3. Sell: Expected to underperform the SP500 producing below-average returns.
ValuEngine does not offer brokerage or investment banking services. ValuEngine adheres to professional standards and abides by
formal codes of ethics that put the interests of clients ahead of their own. The following are specific disclosures made by
ValuEngine with regards to this research report:
1. ValuEngine, Inc. does not make a market in this security.
2. ValuEngine, Inc. has not received compensation from the companies discussed above in the last 12 months.
3. ValuEngine has not managed or co-managed a public offering for any companies in the above report in the last 12 months.
4. None of ValuEngine's management, the analysts involved, nor a member of the research analyst's household serves as an
officer, director or advisory board member of the companies discussed in this report.
5. The research analyst over this company or members of his/her household do not have a financial interest in these
companies discussed in this report.
6. ValuEngine, Inc. or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject
companies.
7. Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with
respect to each security or issuer that the analyst covered in this report: a). all of the views expressed accurately reflect his
or her personal views about those securities or issuers; and b). no part of his or her compensation was, is, or will be, directly
or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.
DISCLAIMERS
This communication is issued by ValuEngine, Inc. This is not a personal recommendation, nor an offer to buy or sell nor a
solicitation to buy or sell any securities, investment products or other financial instruments or services. This material is distributed
for general informational and educational purposes only and is not intended to constitute legal, tax, accounting or investment
advice. The information contained herein accurately reflects the opinion of ValuEngine at the time the report was released. The
opinions of ValuEngine are subject to change at any time without notice and without obligation of notification. No warranty is made
as to the accuracy of the information contained herein. The statements in this document shall not be considered as an objective or
independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal
requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing
ahead of the dissemination or publication of investment research. Intended for recipient only and not for further distribution without
the consent of ValuEngine Inc.
CONTACT US
ValuEngine, Inc., PO Box 399, Melbourne, FL 32902
(321) 325-0519
support@valuengine.com
© 2023 ValuEngine Inc. All rights reserved. (321) 325-0519 support@valuengine.com
page 10